The successful treatment of tumors by lymphocyte infusion in the Department of Hematology won the China Medical Tribune’s Top 10 Domestic Medical News (Events) in 2010 The Department of Hematology created a unique immunotherapy approach for the first time in the international arena by applying high-dose HLA hemipharmonic mother lymphocyte infusion to treat EBV-associated lymphoma, achieving encouraging results and providing a new way of thinking for tumor treatment. We know that Epstein-Barr virus (EBV) is widely infected in the population, and according to serological surveys, more than 90% of the global population is positive for EBV IgG antibodies. EBV proliferates in the epithelial cells of the oropharynx and eventually lurks in B-lymphocytes. In immunocompetent individuals, primary EBV infection may be asymptomatic or present with self-limiting infectious mononucleosis; in cases of congenital immunodeficiency or acquired immunosuppression, EBV infection may present with chronic active EBV infection (CAEBV), causing lymphatic proliferative disorders (LPD) or lymphohistiocytic hemophagocytic syndrome (HLH), and even malignant lymphoma. In the WHO 2008 classification of lymphomas, EBV- LPD in children has been classified as a type of lymphoma. To date, there is no good treatment for this type of disease, and neither antiviral therapy nor chemotherapy has been effective. In recent years, encouraging results have been achieved with cellular immunotherapy in EBV-associated lymphomas, especially in EBV-associated proliferative lymphatic system disorders (PTLD) after solid organ or hematopoietic stem cell transplantation. Post-hematopoietic stem cell transplantation donor lymphocyte infusion (DLI) has been shown to be a promising treatment in patients with EBV-associated lymphoproliferative disorders after transplantation as a form of secondary cellular immunotherapy. However, the incidence of graft-versus-host disease (GVHD) in applied HLA-hemophilic donors is high and correlates with the return dose due to the high number of allogeneic reactive T cells contained in DLI at the same time. The bidirectional blood exchange between mother and fetus during pregnancy can form maternal-maternal microchimerism (MMC) in both mother and child for a long period of time, and in recent years it has been found that the maternal-maternal microchimerism state has the potential to induce mother-child specific immune tolerance, which is beneficial for organ and bone marrow hematopoietic stem cell transplantation between relatives. We applied z-PCR combined with real-time quantitative PCR to detect the presence of microchimerism in many mother-child somatic cells. It was thus envisioned that the application of high-dose HLA hemichimeric maternal lymphocyte infusion for the treatment of EBV-LPD patients would not produce severe graft-versus-host disease (GVHD). The above study suggests that high-dose maternal lymphocyte infusion can be used as a treatment for EBV-associated lymphoma in children. These studies suggest that high-dose maternal lymphocyte infusion may be an effective treatment for EBV-associated lymphoma in children. The results of this study have attracted a lot of attention from the medical community in China and abroad. Professor Ping Zhu and his research group’s paper: High doses of mother’s lymphocyte infusion to treat EBV-positive T cell lymphoproliferative disorders in childhood was accepted by the prestigious international journal BLOOD in September 2010 and published in October 2010. The abstract was accepted by the 51st Annual Meeting of the American Society of Hematology (ASH) and was invited to present orally at the meeting on December 7, 2009. Today, it was named as one of the top ten medical news (events) in China in 2010 by the China Medical Tribune. This is the result of many years of hard work and exploration by the hematology staff. Since the 1990s, the Department of Hematology has been dedicated to the research and practice of cellular immunotherapy, and through the efforts of several experts, has achieved remarkable achievements, which are widely used in the treatment of microscopic residual lesions of various tumors, including solid tumors, the control of refractory recurrent tumors, the treatment of persistent viral infections, and many other fields, making up for the shortage of radiotherapy, and playing a role that radiotherapy and surgery cannot play. The hospital has also established a comprehensive With the support of the hospital, we have established a class 100 clean laboratory for the preparation of lymphokine-activated killer cells (LAK), cytokine-induced killer cells (CIK), antigen-specific cytotoxic T cells (CTL) and other effector cells for cellular immunotherapy. We have found an effective treatment for isolated tumor patients.